Huntington's Disease clinical trials at UC Irvine
2 in progress, 1 open to eligible people
Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort
open to eligible people ages 18 years and up
Enroll-HD is a longitudinal, observational, multinational study that integrates two former Huntington's disease (HD) registries-REGISTRY in Europe, and COHORT in North America and Australasia-while also expanding to include sites in Latin America. More than 30,000 participants have now enrolled into the study. With annual assessments and no end date, Enroll-HD has built a large and rich database of longitudinal clinical data and biospecimens that form the basis for studies developing tools and biomarkers for progression and prognosis, identifying clinically-relevant phenotypic characteristics, and establishing clearly defined endpoints for interventional studies. Periodic cuts of the database are now available to any interested researcher to use in their research - visit www.enroll-hd.org/for-researchers/access-data/ to learn more.
Irvine, California and other locations
Pridopidine Expanded Access Program
Sorry, not accepting new patients
Protocol PL101-HD501: This is an open-label post-trial expanded access program to provide continued treatment with pridopidine for individuals who completed the PROOF-HD study (PL101-HD301) as well as include treatment naïve HD patients ineligible for clinical trials. Protocol PL101-ALS501: This EAP will provide access to pridopidine for up to 200 patients with ALS who are ineligible for clinical trials.
Orange, California and other locations
Our lead scientists for Huntington's Disease research studies include Anna Morenkova.
Last updated: